TABLE 1.
Genetic causes | Trisomy X (47 XXX or mosaic) (Allen et al., 2007; Chapman et al., 2015; Dawood et al., 2018; Kirshenbaum and Orvieto, 2019; Wesevich et al., 2020) |
Deletion of X chromosome (Allen et al., 2007; Chapman et al., 2015; Dawood et al., 2018; Kirshenbaum and Orvieto, 2019; Wesevich et al., 2020) | |
Turner mosaic (45XO/46XX) (Allen et al., 2007; Chapman et al., 2015; Dawood et al., 2018; Kirshenbaum and Orvieto, 2019; Wesevich et al., 2020) | |
Turner syndrome (Torrealday et al., 2017) Fragile X premature (Allen et al., 2007; Chapman et al., 2015; Dawood et al., 2018; Kirshenbaum and Orvieto, 2019; Wesevich et al., 2020) | |
Autoimmune polyglandular syndrome (1 and 2) Blood syndrome | |
BPES | |
Ataxia telangiectasia | |
Fanconi anemia | |
Autoimmune oophoritis | |
Enzyme deficiency | |
• Galactosemia | |
• 17α-hydroxylase deficiency | |
• Aromatase deficiency | |
Infectious diseases | |
• Shigelosis | |
• Chickenpox | |
• Mumps oophoritis | |
• Tuberculosis | |
• Malaria | |
• Cytomegalovirus infection | |
Induced/Others | Chemotherapy |
Alkylating agents | |
• Cyclophosphamide, dacarbazine, chlorambucil, [-2.5pt] melphalan, busulphan, nitrogen mustard, and anthracyclines (doxorubicin) | |
Substituted hydrazine (procarbazine) | |
Bilateral oophorectomy | |
Bilateral ovarian cystectomy | |
Radiation | |
Environmental toxins | |
Pelvic vessel embolization |
Blepharophimosis-Epicanthus inversus syndrome